Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
March 04, 2019 06:30 ET
|
Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...